Suzanne L. Parker

1.8k total citations
101 papers, 1.2k citations indexed

About

Suzanne L. Parker is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Suzanne L. Parker has authored 101 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pharmacology, 23 papers in Molecular Medicine and 22 papers in Epidemiology. Recurrent topics in Suzanne L. Parker's work include Antibiotics Pharmacokinetics and Efficacy (55 papers), Antibiotic Resistance in Bacteria (23 papers) and Bacterial Identification and Susceptibility Testing (15 papers). Suzanne L. Parker is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (55 papers), Antibiotic Resistance in Bacteria (23 papers) and Bacterial Identification and Susceptibility Testing (15 papers). Suzanne L. Parker collaborates with scholars based in Australia, France and United States. Suzanne L. Parker's co-authors include Jason A. Roberts, Jeffrey Lipman, Steven C. Wallis, Glenn R. Parker, Fekade B. Sime, Yarmarly C. Guerra Valero, George Dimοpoulos, Saurabh Pandey, Despoina Koulenti and Therese Starr and has published in prestigious journals such as Applied Physics Letters, Antimicrobial Agents and Chemotherapy and American Political Science Review.

In The Last Decade

Suzanne L. Parker

88 papers receiving 1.2k citations

Peers

Countries citing papers authored by Suzanne L. Parker

Since Specialization

Citations

This map shows the geographic impact of Suzanne L. Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne L. Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne L. Parker more than expected).

Fields of papers citing papers by Suzanne L. Parker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne L. Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne L. Parker. The network helps show where Suzanne L. Parker may publish in the future.

Co-authorship network of co-authors of Suzanne L. Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne L. Parker. A scholar is included among the top collaborators of Suzanne L. Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne L. Parker. Suzanne L. Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ceftriaxone population pharmacokinetics in plasma and cerebrospinal fluid of neurocritical care patients 2025 ·International Journal of Antimicrobial Agents ·(unknown), Aaron J. Heffernan, Xin Liu, Suzanne L. Parker, Menino Osbert Cotta, Steven C. Wallis, (unknown), Therese Starr, (unknown), Gavin M. Joynt, Jeffrey Lipman, Jason A. Roberts	0
2	A pharmacokinetic/pharmacodynamic analysis of intravenous tranexamic acid in adult patients undergoing elective total hip arthroplasty (ORACLE) 2025 ·British Journal of Anaesthesia ·Usha Gurunathan, Robert L. Medcalf, (unknown), Zikou Liu, Xin Liu, Charithani B. Keragala, (unknown), Paul S. Brady, Steven C. Wallis, Jason Roberts, Daniel Mullany, Harshal Nandurkar, Victoria Eley, Suzanne L. Parker	0
3	Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment? 2024 ·Journal of Antimicrobial Chemotherapy ·(unknown), Suzanne L. Parker, (unknown), Fabian Chiong, Cherian Sajiv, (unknown), (unknown), (unknown), Steven Y. C. Tong, (unknown), Steven C. Wallis, Jason A. Roberts, (unknown)	3
4	A review of antimicrobial stability testing guidance for outpatient parenteral antimicrobial therapy programmes: is it time for global harmonization of testing frameworks? 2024 ·JAC-Antimicrobial Resistance ·(unknown), Jason A. Roberts, (unknown), Suzanne L. Parker, R.A. Seaton, Mary J.R. Gilchrist, Fekade B. Sime	0
5	Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis 2023 ·Tropical Medicine and Infectious Disease ·(unknown), Suzanne L. Parker, Cristina Sanches, (unknown), (unknown), (unknown), Mariana Millan Fachi, Marcus Vinícius de Liz, Alexandra B. Souza, Izabella Picinin Safe, Roberto Pontarolo, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts, Marcelo Cordeiro‐Santos	0
6	Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients—a population pharmacokinetic study 2023 ·Journal of Antimicrobial Chemotherapy ·(unknown), (unknown), (unknown), Fabian Chiong, Cherian Sajiv, (unknown), (unknown), (unknown), Steven Y. C. Tong, (unknown), Steven C. Wallis, Jason A. Roberts, Suzanne L. Parker	1
7	Stability of Nafamostat in Intravenous Infusion Solutions, Human Whole Blood and Extracted Plasma: Implications for Clinical Effectiveness Studies 2023 ·Bioanalysis ·(unknown), (unknown), Steven C. Wallis, Suzanne L. Parker, Jason A. Roberts	1
8	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling? 2022 ·Journal of Antimicrobial Chemotherapy ·Yarmarly C. Guerra Valero, Tavey Dorofaeff, M G Coulthard, Louise Sparkes, Jeffrey Lipman, Steven C. Wallis, Jason A. Roberts, Suzanne L. Parker	5
9	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients 2022 ·Antimicrobial Agents and Chemotherapy ·(unknown), (unknown), George Hopkins, Victoria Eley, Rebecca Christensen, André van Zundert, Steven C. Wallis, Jeffrey Lipman, Suzanne L. Parker, Jason A. Roberts	9
10	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients 2021 ·Antibiotics ·Hideo Kato, Suzanne L. Parker, Jason A. Roberts, Mao Hagihara, Nobuhiro Asai, Yuka Yamagishi, David L. Paterson, Hiroshige Mikamo	5
11	Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study 2021 ·Antibiotics ·(unknown), Suzanne L. Parker, Cristina Sanches, (unknown), (unknown), Mariana Millan Fachi, Marcus Vinícius de Liz, Roberto Pontarolo, Jeffrey Lipman, Marcelo Cordeiro‐Santos, Jason A. Roberts	3
12	Kidney Transplant Recipient’s Perceptions of Blood Testing Through Microsampling and Venepuncture 2020 ·Bioanalysis ·(unknown), Suzanne L. Parker, (unknown), George John, Brett McWhinney, Jacobus Ungerer, Andrew J. Mallett, Jason A. Roberts, Helen Healy, Christine E. Staatz	12
13	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain 2020 ·Antimicrobial Agents and Chemotherapy ·Fekade B. Sime, Melissa Lassig‐Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L. Parker, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts	18
14	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction 2019 ·Antimicrobial Agents and Chemotherapy ·Fekade B. Sime, Melissa Lassig‐Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L. Parker, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts	44
15	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens? 2019 ·Expert Review of Anti-infective Therapy ·George Dimοpoulos, Despoina Koulenti, Suzanne L. Parker, Jason A. Roberts, Kostoula Arvaniti, Garyphalia Poulakou	16
16	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration 2019 ·Antimicrobial Agents and Chemotherapy ·Fekade B. Sime, Melissa Lassig‐Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L. Parker, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts	27
17	First‐in‐human phase I study of infusional and bolus schedules of Deflexifol, a novel 5‐fluorouracil and leucovorin formulation, after failure of standard treatment 2019 ·Asia-Pacific Journal of Clinical Oncology ·Philip R. Clingan, Stephen P. Ackland, Daniel Brungs, Paul de Souza, Morteza Aghmesheh, Madhu B. Garg, (unknown), Suzanne L. Parker, (unknown), Marie Ranson	2
18	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study 2019 ·Journal of Pharmaceutical and Biomedical Analysis ·Yarmarly C. Guerra Valero, Jason A. Roberts, Jeffrey Lipman, Cheryl Fourie, Therese Starr, Steven C. Wallis, Suzanne L. Parker	13
19	Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam 2018 ·Antimicrobial Agents and Chemotherapy ·Fekade B. Sime, Saurabh Pandey, (unknown), Suzanne L. Parker, Elizabeth Alexander, Jeffery S. Loutit, Stephanie Durso, David C. Griffith, Jeffrey Lipman, Steven C. Wallis, Jason A. Roberts	27
20	The use and risks of antibiotics in critically ill patients 2016 ·Expert Opinion on Drug Safety ·Kerina J. Denny, Menino Osbert Cotta, Suzanne L. Parker, Jason A. Roberts, Jeffrey Lipman	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact